Approximately 20~25% of the patients with BC demonstrate overexpression or amplification of human epidermal growth factor receptor 2 (HER2) [9,10], which is characterized by low chemosensitivity, strong invasion, high-risk recurrence, and poor prognosis [11,12,13]. The gene discussed is ERBB2; the disease is breast cancer.